On July 28, Infinovo Medical, an innovative medical device developer and manufacturer, garnered tens of millions of yuan in its Series B financing round exclusively led by Vertex Ventures.
The proceeds will be mainly used for the registration approval of the company's new product, the unchecked continuous glucose monitoring system, as well as the global market expansion.
Prior to this round, the company had secured its Series A round from Loyal Valley Capital, Prosperico Ventures and Rongan Venture Capital.
Founded in 2016, Infinovo Medical is a global innovative medical technology company focused on the development and productization of continuous glucose monitoring (CGM) technology.
The company focuses on chronic disease detection device and treatment standards and provides technological sensor tools for chronic disease treatment, enabling users to improve diagnostic accuracy and receive better treatment in an efficient way.
Headquartered in Suzhou, the company now has a production base in Nantong, Jiangsu province, two technical research and development centers in Suzhou and London, and an overseas sales headquarters in Amsterdam, the Netherlands.